# Edwards Lifesciences (EW) Q3 2026 earnings

Results filed 2026-11-04 for the quarter ended 2026-09-30. Source page: https://earnings.opennash.com/companies/ew/2026-q3/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000053/0001099800-26-000053-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Edwards raised its 2026 outlook after TAVR share gains and a new CMS coverage decision, while TMTT growth from PASCAL and EVOQUE added a second structural heart engine.

Edwards' TAVR business grew on a heightened clinical focus on treating aortic stenosis earlier, with modest share gains and stable pricing. CMS finalized an updated TAVR coverage policy, and Japan granted dedicated reimbursement for SAPIEN 3 Ultra RESILIA. In mitral and tricuspid, mitral and tricuspid procedure volumes grew in double digits, and the FDA approved PASCAL Ace with Capture Clarity and PASCAL Precision for tricuspid.
Management says growth from here should come mainly from rising procedure volumes rather than share gains, and it is steering toward earlier-stage disease, with the PROGRESS trial in moderate aortic stenosis as a turning point. The tension is that share gains are fading as a driver, so growth depends on the market expanding. New launches are also being rolled out in a measured way, which limits how fast they can add to growth.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Net sales | $1,715.5 | up 10.5% from a year ago | GAAP |
| Net income | $301.4 | up from $290.3 a year ago | GAAP |
| Gross profit margin | 78.5% | vs 77.9% adjusted a year ago (78.7% adjusted this quarter) | GAAP |
| Operating income | $299.1 | vs $307.1 a year ago | GAAP |
| Operating profit margin | 17.4% | 30.3% adjusted | GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| TAVR | $1,241.6 | up 8.0%, 8.8% constant currency |
| TMTT | $209.5 | up 44.3%, 45.9% constant currency |
| Surgical | $264.4 | up 2.5%, 2.8% constant currency |
| United States | $1,007.6 | up 11.0% |
| Europe | $414.6 | up 6.9%, 8.2% constant currency |
| Japan | $92.0 | up 2.2%, 12.2% constant currency |
| Rest of World | $201.3 | up 20.2%, 18.3% constant currency |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Q4 total sales | fourth quarter of 2026 | $1.67 and $1.75 billion |
| Q4 adjusted EPS | fourth quarter of 2026 | $0.61 to $0.69 |
| Total company sales growth | 2026 | approximately 11.5% |
| TAVR sales growth | 2026 | 9.0% to 9.5% |
| TMTT sales | 2026 | $780 to $790 million |
| Adjusted EPS | 2026 | $2.97 to $3.05 |
| Adjusted gross margin | 2026 | 78% to 79% |
| R&D as a percentage of sales | 2026 | approximately 16.5% |

## Key takeaways

1. **Moderate AS evidence marks a turning point** The PROGRESS trial was presented at TCT and published in The New England Journal of Medicine, which Edwards calls a turning point in managing moderate aortic stenosis. It supports the push toward earlier intervention and a larger treatable population.
2. **CMS finalized an updated TAVR coverage policy** The final national coverage determination aims to expand timely, high-quality access to care and reinforces the multidisciplinary heart team. It is a policy step Edwards names among its priorities for the quarter.
3. **PASCAL approvals widen the mitral and tricuspid toolkit** FDA approved PASCAL Ace with Capture Clarity for degenerative mitral TEER and PASCAL Precision for tricuspid regurgitation, with early clinician feedback described as very positive. The CLASP IITR trial showed PASCAL plus medical therapy was superior to medical therapy alone.
4. **TAVR growth shifts from share gains to volume** Edwards cites modest share gains, stable pricing and strong SAPIEN 3 Ultra RESILIA adoption, plus new dedicated reimbursement in Japan. Management now expects growth to come mainly from procedure volumes, not share gains.
5. **EVOQUE and SAPIEN M3 extend replacement options** EVOQUE gained U.S. and European approval for transjugular access, and SAPIEN M3 with RESILIA tissue was introduced in Europe. Edwards sees strong demand for SAPIEN M3 in patients unsuitable for mitral TEER.

## Questions

**What is driving Edwards' TAVR growth?** Procedure growth from a heightened focus on proactive treatment of severe aortic stenosis, modest share gains, and stable pricing. Growth rates were similar in the U.S. and outside it.
**Which new products did Edwards win approval for this quarter?** PASCAL Ace with Capture Clarity (U.S.), PASCAL Precision for tricuspid (U.S.), SAPIEN M3 RESILIA (Europe), EVOQUE transjugular access (U.S. and Europe), and AUTUS for pediatric patients (U.S.).
**Why does the PROGRESS trial matter?** It was presented at TCT and published in The New England Journal of Medicine, and Edwards says it marks a turning point in the management of moderate aortic stenosis.
**How are mitral and tricuspid therapies performing?** Mitral and tricuspid procedure volumes continued to grow in the double digits, with the PASCAL, EVOQUE and SAPIEN M3 systems all contributing, and TMTT guidance was raised to $780 to $790 million.
**What does management expect to drive growth going forward?** Edwards assumes growth in the fourth quarter and beyond will come mainly from increasing procedure volumes rather than share gains, with positive TAVR procedure trends seen exiting the quarter.

## Slides and investor documents

- [Transcript](https://s27.q4cdn.com/788244549/files/content_files/EW-Q3-2026-Earnings-Call-Transcript.pdf) (Company's official transcript)
- [Webcast](https://event.webcasts.com/starthere.jsp?ei=1778493&tp_key=890ccd3702) (Webcast replay)
- [SEC Filings](https://s27.q4cdn.com/788244549/files/doc_financials/2026/q3/317d4388-55f8-40c7-8d97-854e7dcf20b8.pdf) (Document)

